Clinical Scorecard: N4-acetylcytidine Modification Links Metabolic Changes and Immune Evasion in Cancer: Insights into Mechanisms and Treatment Potential
At a Glance
Category
Detail
Condition
Cancer
Key Mechanisms
N4-acetylcytidine (ac4C) modification enhances mRNA stability and translation of glycolytic enzymes, promoting metabolic reprogramming and immune evasion.
Target Population
Cancer patients exhibiting metabolic reprogramming and immune evasion.
Care Setting
Oncology and cancer research.
Key Highlights
ac4C modification is catalyzed by NAT10 and plays a role in cancer progression.
Enhances stability and translation of glycolytic enzymes, driving the Warburg effect.
Facilitates immune evasion by upregulating PD-L1 and suppressing T cell function.
Targeting NAT10 with inhibitors shows promising preclinical efficacy.
Metabolic reprogramming and immune evasion are interconnected processes.
Guideline-Based Recommendations
Diagnosis
Assess ac4C levels and NAT10 expression in tumor samples.
Management
Consider NAT10 inhibitors in combination with immune checkpoint inhibitors for treatment.
Monitoring & Follow-up
Monitor metabolic markers and immune checkpoint expression in patients.
Risks
Potential for immune-related adverse effects with combination therapies.
Patient & Prescribing Data
Patients with various cancer types exhibiting altered metabolism and immune evasion.
NAT10 inhibition may enhance the efficacy of existing cancer therapies.
Clinical Best Practices
Integrate metabolic and immunological assessments in cancer treatment plans.
Explore combination therapies targeting both metabolic pathways and immune checkpoints.
